Global Drug Delivery Infusion System Market - 2024-2031

Report Overview

The Global Drug Delivery Infusion Systems Market reached US$ 12.8 billion in 2023 and is expected to reach US$ 21.7 billion by 2031 growing with a CAGR of 6.8% during the forecast period 2024-2031.

A drug delivery infusion system is a medical device designed to administer fluids, medications, and therapeutic agents directly into a patient's bloodstream in a controlled and regulated manner. These systems are widely used across various healthcare environments, including hospitals, clinics, ambulatory care settings, and home healthcare. They are essential for delivering pharmaceuticals and treatments for conditions such as chemotherapy, pain management, insulin therapy, and antibiotic administration.

Infusion systems consist of several key components, including a drug reservoir, a mechanism for propulsion, flow controllers, tubing, and an intravenous catheter for administration. The ability to precisely control the delivery of medications is crucial for effective treatment, particularly for patients who require ongoing medication management.

Market Dynamics: Drivers

Rising prevalence of chronic diseases & technological advancements

The demand for the global drug delivery infusion system market is driven by multiple factors. The major drivers fueling the growth of the market are the high prevalence of cancer and chronic diseases such as diabetes, especially in geriatric patients, and increasing technical advancements.

According to the National Centre for Health, in 2022, cancer was the second leading cause of mortality worldwide, with around 1,918,030 new cases registered in 2022. Cancer was responsible for 609,360 deaths all over the world. Moreover, as per WHO the number of new cases is expected to rise by around 70% by 2030.

Similarly, as per WHO data in 2022, it was estimated that there were 20 million new cancer cases and 9.7 million deaths attributed to the disease. Approximately 53.5 million individuals were alive five years after being diagnosed with cancer. Statistically, about 1 in 5 people will develop cancer at some point in their lives, with roughly 1 in 9 men and 1 in 12 women succumbing to the illness.

Moreover, key player's strategies such as partnerships & collaborations, and technological advancements would drive this market growth. For instance, in November 2023, KORU Medical Systems, Inc. announced a new development agreement with a biopharmaceutical manufacturer. This partnership will focus on creating and obtaining regulatory approval for a next-generation infusion system specifically designed for subcutaneous immunoglobulin (SCIg) therapy. This initiative reflects KORU Medical's commitment to improving patient quality of life through innovative infusion technologies.

Also, in June 2023, Eitan Medical announced the launch of Eitan Insights, a new cloud-based infusion management system tailored for home and specialty infusions. The company's infusion systems, Sapphire now equipped with the new universal plug-and-play cellular accessory Sapphire Connect and Avoset, which works with the AvosetGo app, are designed to connect and transmit infusion treatment data to Eitan Insights. This integration enhances the management of infusion therapies by providing real-time data and improving overall patient care.

Restraints

Factors such as product recalls, the high cost of infusion systems, lack of skilled professionals, stringent regulatory requirements, patient safety concerns & improper infusion, and reimbursement challenges are expected to hamper the market.

Market Segment Analysis

The global drug delivery infusion system market is segmented based on product type, application, end-user, and region.

The volumetric infusion pumps segment accounted for approximately 48.2% of the global drug delivery infusion system market share

The volumetric infusion pumps segment is expected to hold the largest market share over the forecast period. Volumetric infusion pumps (VIPs) are sophisticated medical devices designed to deliver precise and continuous amounts of fluids at a wide range of flow rates, from very slow to very fast.

These pumps are widely used in healthcare settings to precisely control the administration of intravenous (IV) medications, fluids, whole blood, and blood products to patients. VIPs enable healthcare professionals to accurately manage the flow of critical substances into a patient's body, ensuring optimal therapeutic effects and minimizing the risk of complications.

Moreover, key players in the industry product launches and approvals that would propel this segment's growth in the market. For instance, in April 2024, Baxter International Inc. announced that its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

This addition of the LVP modality to the Novum IQ Infusion Platform, which already includes Baxter's syringe infusion pump (SYR) with Dose IQ Safety Software and the IQ Enterprise Connectivity Suite, allows clinicians to operate a unified system across various patient care environments. The introduction of the Novum IQ LVP in the U.S. underscores Baxter's dedication to ongoing innovation in the field of infusion therapy.

Similarly, in March 2022, Fresenius Kabi announced that it had received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for its wireless Agilia Connect Infusion System. This system includes the Agilia Volumetric Pump and the Agilia Syringe Pump, both equipped with the Vigilant Software Suite featuring Vigilant Master Med technology.

In addition, key player's strategies such as partnerships & collaborations and mergers & acquisitions would drive this market growth. For instance, in March 2022, Ivenix, Inc. announced that it had entered into a definitive agreement to be acquired by Fresenius Kabi. The acquisition will combine Ivenix's advanced infusion system with Fresenius Kabi's intravenous fluids and infusion therapy offerings, creating a comprehensive portfolio of infusion products for U.S. hospitals. The deal involves a purchase price that includes an upfront payment of $240 million, along with additional milestone payments tied to the achievement of specific commercial and operational targets.

Market Geographical Share

North America accounted for approximately 43.6% of the global drug delivery infusion system market share

North America region is expected to hold the largest market share over the forecast period owing to the growing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions is a key factor driving the drug delivery infusion system market. These illnesses typically necessitate long-term treatment and accurate drug administration, leading to an increased demand for infusion systems, especially insulin pumps and chemotherapy delivery devices.

Advancements in infusion technology, particularly the creation of smart infusion pumps equipped with improved safety features and connectivity, are driving growth in the market. These innovations enhance patient safety and treatment effectiveness, making infusion systems increasingly attractive to healthcare providers. Increased investments in North America's healthcare infrastructure are enabling the widespread adoption of cutting-edge infusion systems

Moreover, a major number of key player's presence, well-advanced healthcare infrastructure, product launches, and approvals would drive this market growth in this region. For instance, in May 2024, Moog Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its CURLIN 8000 Ambulatory Infusion System, designed specifically for home infusion settings. This advanced infusion platform is a new multi-therapy system tailored to meet the unique demands of home care.

Also, in August 2023, ICU Medical announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Plum Duo infusion pump and LifeShield infusion safety software. This new system, which will be available to U.S. customers in early 2024, builds upon the precise delivery capabilities of ICU Medical's award-winning Plum 360 infusion pump.

Similarly, in July 2023, BD announced that its updated BD Alaris Infusion System had received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This approval allows for both the remediation of existing systems and a return to full commercial operations for what is considered the most comprehensive infusion system available in the United States.

Market Segmentation

By Product Type

• Volumetric Infusion Pumps
• Syringe Infusion Systems
• Ambulatory Infusion Systems
• Implantable Infusion Systems
• Insulin Infusion Pumps
• Enteral Infusion Systems
• Large Volume Infusion Systems
• Patient Controlled Analgesia (PCA)
• Elastomeric Infusion Pumps

By Application

• Oncology/Chemotherapy
• Diabetes
• Analgesia
• Nutrition
• Hematology
• Pediatrics
• Others

By End-User

• Hospitals
• Specialty Clinics
• Ambulatory Surgery Centers
• Homecare Settings

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • The rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Market Competitive Landscape

The major global players in the drug delivery infusion system market include Medtronic, Eitan Medical, B. Braun SE, BD, Baxter, Terumo Corporation, Insulet Corporation., Fresenius Kabi AG, Arcomed, and ICU Medical, Inc. among others.

Key Developments

• In January 2024, AbbVie introduced PRODUODOPA (foslevodopa/foscarbidopa) in the European Union, marking it as the first and only subcutaneous infusion therapy that provides continuous 24-hour delivery of levodopa for individuals with advanced Parkinson's disease.
• In December 2023, TriSalus Life Sciences Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has established a new Healthcare Common Procedure Coding System (HCPCS) code for procedures involving the company's TriNav infusion system.
• In June 2023, B. Braun launched its latest infusion management software, DoseTrac Enterprise, which provides organizations with a combination of real-time monitoring and historical reporting capabilities to gain deeper insights into their infusion pump fleet and related data. This new software platform enables healthcare providers to better comprehend and optimize their infusion pump infrastructure by offering a blend of live data visualizations and in-depth retrospective analytics.
• In April 2023, Eitan Medical announced the launch of its innovative Avoset-connected infusion system, a multi-therapy ambulatory infusion pump designed to revolutionize post-acute care and specialty infusion therapy. This advanced system features compact and user-friendly technology that allows for remote monitoring of infusion treatment data, enhancing patient safety and improving the overall user experience.
• In February 2023, Mindray introduced its BeneFusion i Series and u Series infusion systems, designed to enhance medication safety across various clinical environments. These systems feature high precision, adaptive customization, and user-friendly interfaces, ensuring reliable medication delivery.

Why Purchase the Report?

• To visualize the global drug delivery infusion system market segmentation based on product type, application, end-user, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the drug delivery infusion system market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The global drug delivery infusion system market report would provide approximately 62 tables, 63 figures, and 183 pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies